中慧生物旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单

老虎资讯综合

Aug 13

8月13日，中慧生物-B盘初再飙逾15%，总市值超200亿港元！旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单。

公司发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚单位疫苗。

集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1和H3N2亚型)和两种乙型流感病毒(Yamagata和Victoria谱系)提供广泛保护。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163046330"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163046330\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163046330?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","is_english":false,"pubTime":"2025-08-13 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163046330","market":"hk","top_or_hot":-1,"title":"中慧生物旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单","media":"老虎资讯综合","content":"<html><head></head><body><p>8月13日，<a href=\"https://laohu8.com/S/02627\">中慧生物-B</a>盘初再飙逾15%，总市值超200亿港元！旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a92c8643e4a3940cd305b4e63c23f37a\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p>公司发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚单位疫苗。</p><p>集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1和H3N2亚型)和两种乙型流感病毒(Yamagata和<a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>谱系)提供广泛保护。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中慧生物旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中慧生物旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-08-13 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>8月13日，<a href=\"https://laohu8.com/S/02627\">中慧生物-B</a>盘初再飙逾15%，总市值超200亿港元！旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a92c8643e4a3940cd305b4e63c23f37a\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p>公司发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚单位疫苗。</p><p>集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1和H3N2亚型)和两种乙型流感病毒(Yamagata和<a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>谱系)提供广泛保护。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"","article_id":"1163046330","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163046330","pubTimestamp":1755048719,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"8月13日，$中慧生物-B(02627)$盘初再飙逾15%，总市值超200亿港元！旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02627":"中慧生物-B"},"translate_title":"Huier Kangxin, a subsidiary of Zhonghui Biotech, was selected as the only vaccine into the preliminary review list of national medical insurance innovative drugs","themeId":"feece2e65780deb9a483e9ba56c7acc5","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/d5e2d016f7ab9ac8020c1d3b7f93b2f6","symbols_score_info":{"02627":1},"content_text":"8月13日，中慧生物-B盘初再飙逾15%，总市值超200亿港元！旗下慧尔康欣作为唯一疫苗入选国家医保创新药品初审名单。公司发布公告，根据国家医疗保障局于2025年8月12日发布的公告，本年度国家商业健康保险创新药品目录通过初步审查的名单中，包括唯一一款疫苗产品—四价流感病毒亚单位疫苗。集团的商品名为慧尔康欣的四价流感病毒亚单位疫苗于2023年5月获得中国国家药品监督管理局的新药申请(NDA)批准，可用于三岁及以上人群(就含病毒株血凝素浓度而言规格为15μg/0.5ml)，为截至2025年7月21日在中国获批的首款且唯一一款四价流感病毒亚单位疫苗，旨在针对两种甲型流感病毒(H1N1和H3N2亚型)和两种乙型流感病毒(Yamagata和Victoria谱系)提供广泛保护。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风险低等优势。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}